Brain-derived neurotrophic factor serum levels correlate with cognitive performance in parkinson’s disease patients with mild cognitive impairment

Frontiers in Behavioral Neuroscience

Volumn 9, Issue September, 2015, Pages

  Costa, Alberto ^a,b   Peppe, Antonella ^b   Carlesimo, Giovanni Augusto ^b,c   Zabberoni, Silvia ^b   Scalici, Francesco ^b   Caltagirone, Carlo ^b,c   Angelucci, Francesco ^b  

^a NICCOLÒ CUSANO UNIVERSITY   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

BDNF; Cognitive functions; Mild cognitive impairment; Neuropsychological deficits; Parkinson s disease

Indexed keywords

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR;

AGED; ARTICLE; ATTENTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPISODIC MEMORY; EXECUTIVE FUNCTION; HUMAN; MENTAL PERFORMANCE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; PARKINSON DISEASE; PROTEIN BLOOD LEVEL; SPATIAL MEMORY; VISUAL MEMORY; WORKING MEMORY;

EID: 84942860454     PISSN: 16625153     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnbeh.2015.00253     Document Type: Article

References (74)

1. Agid, Y., Ruberg, M., Javoy-Agid, F., Hirsch, E., Raisman-Vozari, R., Vyas, S., et al. (1993). Are dopaminergic neurons selectively vulnerable to Parkinson's disease? Adv. Neurol. 60, 148-164.
2. Alfimova, M. V., Korovaitseva, G. I., Lezheiko, T. V., and Golimbet, V. E. (2012). Effect of BDNF Val66Met polymorphism on normal variability of executive functions. Bull. Exp. Biol. Med. 152, 606-609. doi: 10.1007/s10517-012-1587-x
3. Alonso-Navarro, H., Jimenez-Jimenez, F. J., Garcia-Martin, E., and Agundez, J. A. (2014). Genomic and pharmacogenomic biomarkers of Parkinson's disease. Curr. Drug Metab. 15, 129-181. doi: 10.2174/138920021502140327175404
4. Angelucci, F., Peppe, A., Carlesimo, G. A., Serafini, F., Zabberoni, S., Barban, F., et al. (2015). A pilot study on the effect of cognitive training on BDNF serum levels in individuals with Parkinson's disease. Front. Hum. Neurosci. 9:130. doi: 10.3389/fnhum.2015.00130
5. Barbarotto, R., Laiacona, M., Frosio, R., Vecchio, M., Farinato, A., and Capitani, E. (1998). A normative study onvisual reaction times and two stroop colour-word tests. Ital. J. Neurol. Sci. 19, 161-670. doi: 10.1007/bf00831566
6. Baydyuk, M., and Xu, B. (2014). BDNF signaling and survival of striatal neurons. Front. Cell. Neurosci. 8:254. doi: 10.3389/fncel.2014.00254
7. Beck, A. T., Ward, C. H., Mendelson, M., Mock, M., and Erbaugh, J. (1961). An inventory for measuring depression. Arch. Gen. Psychiatry 4, 561-571. doi: 10.1001/archpsyc.1961.01710120031004
8. Biatecka, M., Kurzawski, M., Roszmann, A., Robowski, P., Sitek, E. J., Honczarenko, K., et al. (2014). BDNF G196A (Val66Met) polymorphism associated with cognitive impairment in Parkinson's disease. Neurosci. Lett. 561, 86-90. doi: 10.1016/j.neulet.2013.12.051
9. Camps, M., Kelly, P. H., and Palacios, J. M. (1990). Autoradiographic localization of dopamine D1 and D2 receptors in the brain of several mammalian species. J. Neural Transm. Gen. Sect. 80, 105-127. doi: 10.1007/bf01257077
10. Capasso, R., and Miceli, G. (2001). Esame Neuropsicohgico Dell’Afasia. Milano: Springer Verlag.
11. Carlesimo, G. A., Buccione, I., Fadda, L., Graceffa, A., Mauri, M., Lorusso, S., et al. (2002). Standardizzazione di due test di memoria per uso clinico: breve racconto e figura di Rey. Nuova Riv. di Neurol. 12, 1-13.
12. Carlesimo, G. A., Caltagirone, C., and Gainotti, G. (1996). The mental deterioration battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. the group for the standardization of the mental deterioration battery. Eur. Neurol. 36, 378-384. doi: 10.1159/000117297
13. Cohen, J. D., Braver, T. S., and Brown, J. W. (2002). Computational perspectives on dopamine function in prefrontal cortex. Curr. Opin. Neurobiol. 12,223-229. doi: 10.1016/s0959-4388(02)00314-8
14. Conte, A., Khan, N., Defazio, G., Rothwell, J. C., and Berardelli, A. (2013). Pathophysiology of somatosensory abnormalities in parkinson disease. Nat. Rev. Neurol. 9, 687-697. doi: 10.1038/nrneurol.2013.224
15. Cools, R. (2006). Dopaminergic modulation ofcognitive function-implications for L-DOPA treatment in Parkinson's disease. Neurosci. Biobehav. Rev. 30, 1-23. doi: 10.1016/j.neubiorev.2005.03.024
16. Cools, R., and D'Esposito, M. (2011). Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biol. Psychiatry 69, e113-e125. doi: 10.1016/j.biopsych.2011.03.028
17. Costa, A., Monaco, M., Zabberoni, S., Peppe, A., Perri, R., Fadda, L., et al. (2014a). Free and cued recall memory in Parkinson's disease associated with amnestic mild cognitive impairment. PLoS One 9:e86233. doi: 10.1371/journal.pone.0086233
18. Costa, A., Peppe, A., Mazzu, I., Longarzo, M., Caltagirone, C., and Carlesimo, G. A. (2014b). Dopamine treatment and cognitive functioning in individuals with Parkinson's disease: the "cognitive flexibility" hypothesis seems to work. Behav. Neurol. 2014:260896. doi: 10.1155/2014/260896
19. Costa, A., Bagoj, E., Monaco, M., Zabberoni, S., De Rosa, S., Papantonio, A. M., et al. (2014c). Standardization and normative data obtained in the Italian population for a new verbal fluency instrument, the phonemic/semantic alternate fluency test. Neurol. Sci. 35, 365-372. doi: 10.1007/s10072-013-1520-8
20. Costa, A., Peppe, A., Dell'Agnello, G., Caltagirone, C., and Carlesimo, G. A. (2009). Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory. Neuropsychologia 47, 1374-1381. doi: 10.1016/j.neuropsychologia.2009.01.039
21. Dai, L., Wang, D., Meng, H., Zhang, K., Fu, L., Wu, Y., et al. (2013). Association between the BDNF G196A and C270T polymorphisms and Parkinson's disease: a meta-analysis. Int. J. Neurosci. 123, 675-683. doi: 10.3109/00207454.2013.798784
22. Dirnberger, G., and Jahanshahi, M. J. (2013). Executive dysfunction in Parkinson's disease: a review. J. Neuropsychol. 7, 193-224. doi: 10.1111/jnp.12028
23. Dubois, B., Burn, D., Goetz, C., Aarsland, D., Brown, R. G., Broe, G. A., et al. (2007). Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov. Disord. 22, 2314-2324. doi: 10.1002/mds.21844
24. Folstein, M. F., Folstein, S. E., and McHugh, P. R. (1975). “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189-198. doi: 10.1016/0022-3956(75)90026-6
25. Foltynie, T., Lewis, S. G., Goldberg, T. E., Blackwell, A. D., Kolachana, B. S., Weinberger, D. R., et al. (2005). The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson's disease. J. Neurol. 252, 833-838. doi: 10.1007/s00415-005-0756-5
26. Frank, M. (2005). Dynamic dopamine modulation in the basal ganglia: a neurocomputational account of cognitive deficits in medicated and non-medicated parkinsonism. J. Cogn. Neurosci. 17, 51-72. doi: 10.1162/0898929052880093
27. Gajewski, P. D., Hengstler, J. G., Golka, K., Falkenstein, M., and Beste, C. (2011). The Met-allele of the BDNF Val66Met polymorphism enhances task switching in elderly. Neurobiol. Aging 32, 2327.e7-2327.e19. doi: 10.1016/j.neurobiolaging.2011.06.010
28. Galloway, E. M., Woo, N. H., and Lu, B. (2008). Persistent neural activity in the prefrontal cortex: a mechanism by which bdnf regulates working memory? Prog. Brain Res. 169,251-266. doi: 10.1016/s0079-6123(07)00015-5
29. Giovagnoli, A. R., Del Pesce, M., Mascheroni, S., Simoncelli, M., Laiacona, M., and Capitani, E. (1996). Trailmaking test: normative values from 287 normal adults controls. Ital. J. Neurol. Sci. 17, 305-309. doi: 10.1007/bf01997792
30. Gómez-Palacio-Schjetnan, A., and Escobar, M. L. (2013). Neurotrophins and synaptic plasticity. Curr. Top. Behav. Neurosci. 15, 117-136. doi: 10.1007/78542012231
31. Gorski, J. A., Balogh, S. A., Wehner, J. M., and Jones, K. R. (2003). Learning deficits in forebrain-restricted brain-derived neurotrophic factor mutant mice. Neuroscience 121, 341-354. doi: 10.1016/s0306-4522(03)00426-3
32. Gottmann, K., Mittmann, T., and Lessmann, V. (2009). BDNF signaling in the formation, maturation and plasticity of glutamatergic and GABAergic synapses. Exp. Brain Res. 199, 203-234. doi: 10.1007/s00221-009-1994-z
33. Greene, J. G. (2014). Causes and consequences of degeneration of the dorsal motor nucleus of the vagus nerve in Parkinson's disease. Antioxid. Redox. Signal. 21, 649-667. doi: 10.1089/ars.2014.5859
34. Guerini, F. R., Beghi, E., Riboldazzi, G., Zangaglia, R., Pianezzola, C., Bono, G., et al. (2009). BDNF Val66Met polymorphism is associated with cognitive impairment in italian patients with Parkinson's disease. Eur. J. Neurol. 16, 1240-1245. doi: 10.1111/j.1468-1331.2009.02706.x
35. Guillin, O., Griffon, N., Bezard, E., Leriche, L., Diaz, J., Gross, C., et al. (2003). Brain-derived neurotrophic factor controls dopamine D3 receptor expression: therapeutic implications in Parkinson's disease. Eur. J. Pharmacol. 480, 89-95. doi: 10.1016/j.ejphar.2003.08.096
36. Gyárfás, T., Knuuttila, J., Lindholm, P., Rantamaki, T., and Castrén, E. (2010). Regulation of brain-derived neurotrophic factor (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-parkinsonian drug therapy in vivo. Cell. Mol Neurobiol. 30, 361-368. doi: 10.1007/s10571-009-9458-3
37. He, Y. Y., Zhang, X. Y., Yung, W. H., Zhu, J. N., and Wang, J. J. (2013). Role of BDNF in central motor structures and motor diseases. Mol Neurobiol. 48, 783-793. doi: 10.1007/s12035-013-8466-y
38. Heldt, S. A., Stanek, L., Chhatwal, J. P., and Ressler, K. J. (2007). Hippocampus-specific deletion of BDNF in adult mice impairs spatial memory and extinction of aversive memories. Mol Psychiatry 12, 656-670. doi: 10.1038/sj.mp.4001957
39. Howells, D. W., Porritt, M. J., Wong, J. Y., Batchelor, P. E., Kalnins, R., Hughes, A. J., et al. (2000). Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp. Neurol. 166, 127-135. doi: 10.1006/exnr.2000.7483
40. Hughes, A. J., Daniel, S. E., Kilford, L., and Lees, A. J. (1992). Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55, 181-184. doi: 10.1136/jnnp.55.3.181
41. Hyman, C., Hofer, M., Barde, Y. A., Juhasz, M., Yancopoulos, G. D., Squinto, S. P., et al. (1991). BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350, 230-232. doi: 10.1038/350230a0
42. Jahanshahi, M., Jones, C. R., Zijlmans, J., Katzenschlager, R., Lee, L., Quinn, N., et al. (2010). Dopaminergic modulation of striato-frontal connectivity during motor timing in Parkinson's disease. Brain 133, 727-745. doi: 10.1093/brain/awq012
43. Jiménez-Jiménez, F. J., Alonso-Navarro, H., García-Martín, E., and Agúndez, J. A. (2014). Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease. Front. Cell. Neurosci. 8:369. doi: 10.3389/fncel.2014.00369
44. Karamohamed, S., Latourelle, J. C., Racette, B. A., Perlmutter, J. S., Wooten, G. F., Lew, M., et al. (2005). BDNF genetic variants are associated with onset age of familial parkinson disease: gene PD Study. Neurology 65, 1823-1825. doi: 10.1212/01.wnl.0000187075.81589.fd
45. Koponen, E., VSikar, V., Riekki, R., Saarelainen, T., Rauramaa, T., Rauvala, H., et al. (2004). Transgenic mice overexpressing the full-length neurotrophin receptor trkB exhibit increased activation of the trkB-PLCgamma pathway, reduced anxiety and facilitated learning. Mol Cell. Neurosci. 26, 166-181. doi: 10.1016/j.mcn.2004.01.006
46. Koven, N. S., and Collins, L. R. (2014). Urinary brain-derived neurotrophic factor as a biomarker of executive functioning. Neuropsychobiology 69, 227-234. doi: 10.1159/000362242
47. Lawton, M. P., and Brody, E. M. (1969). Assessment of older people; self-maintaining and instrumental activity of daily living. Gerontologist 9, 179-186. doi: 10.1093/geront/9.3_part_1.179
48. Leal, G., Afonso, P. M., Salazar, I. L., and Duarte, C. B. (2014). Regulation of hippocampal synaptic plasticity by BDNF. Brain Res. 1621, 82-101. doi: 10.1016/j.brainres.2014.10.019
49. Leentjens, A. F., Dujardin, K., Marsh, L., Martinez-Martin, P., Richard, I. H., Starkstein, S. E., et al. (2008). Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov. Disord. 23, 2004-2014. doi: 10.1002/mds.22229
50. Leverenz, J. B., Watson, G. S., Shofer, J., Zabetian, C. P., Zhang, J., and Montine, T. J. (2011). Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease. Parkinsonism Relat. Disord. 17, 61-64. doi: 10.1016/j.parkreldis.2010.10.003
51. Li, M., Dai, F. R., Du, X. P.,Yang, Q. D., Zhang, X., and Chen, Y. (2012). Infusion of BDNF into the nucleus accumbens of aged rats improves cognition and structural synaptic plasticity through PI3K-ILK-Akt signaling. Behav. Brain Res. 231, 146-153. doi: 10.1016/j.bbr.2012.03.010
52. Lindenbach, D., and Bishop, C. (2013). Critical involvement ofthe motor cortex in the pathophysiology and treatment ofParkinson's disease. Neurosci. Biobehav. Rev. 37, 2737-2750. doi: 10.1016/j.neubiorev.2013.09.008
53. Litvan, I., Goldman, J. G., Troster, A. I., Schmand, B. A., Weintraub, D., Petersen, R. C., et al. (2012). Diagnostic criteria for mild cognitive impairment in Parkinson's disease: movement disorder society Task force guidelines. Mov. Disord. 27, 349-356. doi: 10.1002/mds.24893
54. Lu, W., Zhang, C., Yi, Z., Li, Z., Wu, Z., and Fang, Y. (2012). Association between BDNF Val66Met polymorphism and cognitive performance in antipsychotic-naive patients with schizophrenia. J. Mol Neurosci. 47, 505-510. doi: 10.1007/s12031-012-9750-4
55. MacDonald, P. A., and Monchi, O. (2011). Differential effects of dopaminergic therapies on dorsal and ventral striatum in Parkinson's disease: implications for cognitive function. Parkinsons Dis. 2011:572743. doi: 10.4061/2011/572743
56. Marin, R. S., Biedrzycki, R. C., and Firinciogullari, S. (1991). Reliability and validity of the apathy evaluation scale. Psychiatry Res. 38, 143-162. doi: 10.1016/0165-1781(91)90040-v
57. Monaco, M., Costa, A., Caltagirone, C., and Carlesimo, G. A. (2013). Forward and backward span for verbal and visuo-spatial data: standardization and normative data from an italian adult population. Neurol. Sci. 34, 749-754. doi: 10.1007/s10072-012-1130-x
58. Monteggia, L. M., Barrot, M., Powell, C. M., Berton, O., Galanis, V., Gemelli, T., et al. (2004). Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc. Natl. Acad. Sci. USA 101, 10827-10832. doi: 10.1073/pnas.0402141101
59. Murer, M. G., Yan, Q., and Raisman-Vozari, R. (2001). Brain-derived neurotrophic factor in the control human brain and in Alzheimer's disease and Parkinson's disease. Prog. Neurobiol. 63, 71-124. doi: 10.1016/s0301-0082(00)00014-9
60. Nocentini, U., Di Vincenzo, S., Panella, M., Pasqualetti, P., and Caltagirone, C. (2002). La valutazione delle funzioni esecutive nella pratica neuropsicologica; dal modified card sorting test al modified card sorting test-roma version. Dati di standardizzazione. Nuova Riv. di Neurol. 12, 13-24.
61. Pálhagen, S., Qi, H., Mártensson, B., Wálinder, J., Granérus, A. K., and Svenningsson, P. (2010). Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression. J. Neurol. 257, 524-532. doi: 10.1007/s00415-009-5353-6
62. Rana, A. Q., Ahmed, U. S., Chaudry, Z. M., and Vasan, S. (2015). Parkinson's disease: a review of non-motor symptoms. Expert. Rev. Neurother. 15, 549-562. doi: 10.1586/14737175.2015.1038244
63. Robbins, T. W., and Cools, R. (2014). Cognitive deficits in Parkinson's disease: a cognitive neuroscience perspective. Mov. Disord. 29, 597-607. doi: 10.1002/mds.25853
64. Salehi, Z., and Mashayekhi, F. (2009). Brain-derived neurotrophic factor concentrations in the cerebrospinal fluid of patients with Parkinson's disease. J. Clin. Neurosci. 16, 90-93. doi: 10.1016/j.jocn.2008.03.010
65. Savitz, J., Solms, M., and Ramesar, R. (2006). The molecular genetics of cognition: dopamine, COMT and BDNF. Genes Brain Behav. 5, 311-328. doi: 10.1111/j.1601-183x.2005.00163.x
66. Scalzo, P., Kümmer, A., Bretas, T. L., Cardoso, F., and Teixeira, A. L. (2010). Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson's disease. J. Neurol. 257, 540-545. doi: 10.1007/s00415-009-5357-2
67. Stacy, M. (2011). Nonmotor symptoms in Parkinson's disease. Int. J. Neurosci. 121(Suppl. 2), 9-17. doi: 10.3109/00207454.2011.620196
68. Svetel, M., Pekmezovic, T., Markovic, V., Novakovic, I., Dobricic, V., Djuric, G., et al. (2013). No association between brain-derived neurotrophic factor G196A polymorphism and clinical features of parkinson's disease. Eur. Neurol. 70, 257-262. doi: 10.1159/000352033
69. Tükel, R., Gürvit, H., Ozata, B., Oztürk, N., Ertekin, B. A., Ertekin, E., et al. (2012). Brain-derived neurotrophic factor gene Val66Met polymorphism andcognitive function in obsessive compulsive disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 159, 850-858. doi: 10.1002/ajmg.b.32092
70. Visser, M., Verbaan, D., van Rooden, S., Marinus, J., van Hilten, J., and Stiggelbout, A. (2009). A longitudinal evaluation of health-related quality of life of patients with Parkinson's disease. Value Health 12, 392-396. doi: 10.1111/j.1524-4733.2008.00430.x
71. Wilson, B. A., Evans, J. J., Emslie, H., Alderman, N., and Burgess, P. (1998). The development of an ecologically valid test for assessing patients with a dysexecutive syndrome. Neuropsychol. Rehab. 8, 213-228. doi: 10.1080/713755570
72. Woo, N. H., and Lu, B. (2006). Regulation of cortical interneurons by neurotrophins: from development to cognitive disorders. Neuroscientist 12, 43-56. doi: 10.1177/1073858405284360
73. Yeterian, E. H., and Pandya, D. N. (1991). Prefrontostriatal connections in relation to cortical architectonic organization in rhesus monkeys. J. Comp. Neurol. 312, 43-67. doi: 10.1002/cne.903120105
74. Ziebell, M., Khalid, U., Klein, A. B., Aznar, S., Thomsen, G., Jensen, P., et al. (2012). Striatal dopamine transporter binding correlates with serum BDNF levels in patients with striatal dopaminergic neurodegeneration. Neurobiol. Aging 33, 428.e1-428.e5. doi: 10.1016/j.neurobiolaging.2010.11.010